score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G1049R	0.2808	146.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G1049R (Missense)	1	KIRC_SOMATICSNIPER	TCGA-A3-3357-01A-02D-1421-08	TCGA-A3-3357-11A-01D-1421-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047L	0.3411	129.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047L (Missense)	1	KIRC_SOMATICSNIPER	TCGA-BP-4960-01A-01D-1462-08	TCGA-BP-4960-11A-01D-1462-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.G742D	0.1711	76.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.G742D (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5698-01A-11D-1669-08	TCGA-B0-5698-10A-01D-1669-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.Y82N	0.3014	282.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.Y82N (Missense)	1	KIRC_SOMATICSNIPER	TCGA-A3-A8OV-01A-11D-A36X-10	TCGA-A3-A8OV-10A-01D-A370-10
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.H805R	0.2797	118.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.H805R (Missense)	1	KIRC_SOMATICSNIPER	TCGA-B0-5713-01A-11D-1669-08	TCGA-B0-5713-11A-01D-1669-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.S1042N	0.3196	219.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.S1042N (Missense)	1	KIRC_SOMATICSNIPER	TCGA-B0-5116-01A-02D-1421-08	TCGA-B0-5116-11A-01D-1421-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.G637W	0.2353	34.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.G637W (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-4908-01A-01D-1429-08	TCGA-CJ-4908-11A-01D-1429-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.V242L	0.3281	448.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.V242L (Missense)	0	KIRC_SOMATICSNIPER	TCGA-CZ-5467-01A-01D-1501-10	TCGA-CZ-5467-11A-01D-1501-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.F889V	0.3022	278.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.F889V (Missense)	0	KIRC_SOMATICSNIPER	TCGA-CJ-5680-01A-11D-1534-10	TCGA-CJ-5680-11A-01D-1535-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.D1026E	0.3678	174.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.D1026E (Missense)	0	KIRC_SOMATICSNIPER	TCGA-CW-5585-01A-01D-1534-10	TCGA-CW-5585-11A-01D-1535-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E1030D	0.244	168.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E1030D (Missense)	0	KIRC_SOMATICSNIPER	TCGA-B0-5121-01A-02D-1421-08	TCGA-B0-5121-11A-01D-1421-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R250*	0.301	588.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R250* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-B0-5703-01A-11D-1534-10	TCGA-B0-5703-11A-01D-1534-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R2419*	0.2667	75.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R2419* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-CJ-5686-01A-11D-1669-08	TCGA-CJ-5686-11A-01D-1669-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R2580*	0.2132	136.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R2580* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-B0-5097-01A-01D-1421-08	TCGA-B0-5097-11A-01D-1421-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.E3A	0.4051	158.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.E3A (Missense)	1	KIRC_SOMATICSNIPER	TCGA-A3-A8OV-01A-11D-A36X-10	TCGA-A3-A8OV-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S407L	0.1969	127.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S407L (Missense)		KIRC_SOMATICSNIPER	TCGA-B4-5832-01A-11D-1669-08	TCGA-B4-5832-10A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E846*	0.3821	123.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E846* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-CJ-4903-01A-01D-1429-08	TCGA-CJ-4903-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E981*	0.3798	258.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E981* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-BP-4985-01A-01D-1462-08	TCGA-BP-4985-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Y559*	0.3366	101.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y559* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-A3-3372-01A-01W-0886-08	TCGA-A3-3372-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.R30S	0.2353	17.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.R30S (Missense)	0	KIRC_SOMATICSNIPER	TCGA-A3-3319-01A-01D-0966-08	TCGA-A3-3319-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q440*	0.2917	24.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q440* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-BP-4999-01A-01D-1462-08	TCGA-BP-4999-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q719*	0.6211	161.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q719* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-G6-A8L8-01A-21D-A36X-10	TCGA-G6-A8L8-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Y1428*	0.2097	596.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y1428* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-BP-5169-01A-01D-1429-08	TCGA-BP-5169-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R58*	0.4153	118.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R58* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-BP-4987-01A-01D-1462-08	TCGA-BP-4987-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q170*	0.3199	422.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q170* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-BP-5195-01A-02D-1429-08	TCGA-BP-5195-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q1298*	0.3596	228.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q1298* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-CJ-5676-01A-11D-1534-10	TCGA-CJ-5676-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E368*	0.3271	107.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E368* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-B0-5399-01A-01D-1501-10	TCGA-B0-5399-10A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E1132*	0.3238	105.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1132* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-B4-5836-01A-11D-1669-08	TCGA-B4-5836-10A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q188*	0.3852	244.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q188* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-DV-5566-01A-01D-1534-10	TCGA-DV-5566-10A-01D-1535-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.S502*	0.8551	69.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.S502* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-EU-5907-01A-11D-1669-08	TCGA-EU-5907-10A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R710*	0.4167	144.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R710* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-B0-5700-01A-11D-1534-10	TCGA-B0-5700-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Y1261*	0.4608	102.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y1261* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-CZ-5982-01A-11D-1669-08	TCGA-CZ-5982-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q481*	0.6316	95.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q481* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-A3-3382-01A-01D-0966-08	TCGA-A3-3382-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.K96*	0.3659	82.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K96* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-BP-4982-01A-01D-1462-08	TCGA-BP-4982-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q422*	0.2293	266.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q422* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-BP-5170-01A-01D-1429-08	TCGA-BP-5170-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E160*	0.5976	333.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E160* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-CZ-5454-01A-01D-1501-10	TCGA-CZ-5454-11A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.K243*	0.3702	181.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K243* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-A3-3373-01A-02D-1421-08	TCGA-A3-3373-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q209*	0.5153	163.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q209* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-B0-5694-01A-11D-1534-10	TCGA-B0-5694-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q869*	0.4833	60.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q869* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-BP-5180-01A-01D-1429-08	TCGA-BP-5180-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V219I	0.2882	170.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.V219I (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5110-01A-01D-1421-08	TCGA-B0-5110-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S649T	0.3938	160.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S649T (Missense)		KIRC_SOMATICSNIPER	TCGA-A3-3385-01A-02D-1421-08	TCGA-A3-3385-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R1010*	0.2143	28.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1010* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-DV-A4W0-01A-11D-A25V-10	TCGA-DV-A4W0-10A-01D-A25V-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.K485*	0.2901	131.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K485* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-CJ-4908-01A-01D-1429-08	TCGA-CJ-4908-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Q779*	0.3725	102.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q779* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-A3-3387-01A-01D-1534-10	TCGA-A3-3387-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R921*	0.2401	379.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R921* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-CZ-5455-01A-01D-1501-10	TCGA-CZ-5455-11A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R690*	0.4743	175.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R690* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-B0-5085-01A-01D-1462-08	TCGA-B0-5085-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E457*	0.4124	97.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E457* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-B0-5115-01A-01D-1421-08	TCGA-B0-5115-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.Y666*	0.3697	165.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y666* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-B0-5711-01A-11D-1669-08	TCGA-B0-5711-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E1016*	0.1923	52.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1016* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-CJ-4913-01A-01D-1429-08	TCGA-CJ-4913-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R710*	0.2694	219.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R710* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-BP-5187-01A-01D-1429-08	TCGA-BP-5187-11A-01D-1429-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Y176*	0.3463	618.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Y176* (Nonsense)	1	KIRC_SOMATICSNIPER	TCGA-DV-5568-01A-01D-1534-10	TCGA-DV-5568-10A-01D-1535-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Splice Site	p.X212_splice	0.2034	408.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.X212_splice (Splice Site)	1	KIRC_SOMATICSNIPER	TCGA-A3-3308-01A-01D-0966-08	TCGA-A3-3308-11A-01D-0966-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.S865P	0.3695	203.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.S865P (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-5682-01A-11D-1534-10	TCGA-CJ-5682-11A-01D-1535-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.K1352N	0.203	202.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.K1352N (Missense)		KIRC_SOMATICSNIPER	TCGA-B8-5163-01A-01D-1421-08	TCGA-B8-5163-10A-01D-1421-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.D282E	0.2308	91.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.D282E (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5694-01A-11D-1534-10	TCGA-B0-5694-11A-01D-1534-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.E1006*	0.2366	93.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E1006* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-CJ-6032-01A-11D-1669-08	TCGA-CJ-6032-11A-01D-1669-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.N2494Y	0.3162	525.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.N2494Y (Missense)	1	KIRC_SOMATICSNIPER	TCGA-CZ-5451-01A-01D-1501-10	TCGA-CZ-5451-11A-01D-1501-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.A749T	0.3285	411.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.A749T (Missense)	1	KIRC_SOMATICSNIPER	TCGA-B0-5703-01A-11D-1534-10	TCGA-B0-5703-11A-01D-1534-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.V143D	0.3248	117.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.V143D (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5102-01A-01D-1421-08	TCGA-B0-5102-11A-01D-1421-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.T909I	0.2237	76.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.T909I (Missense)	1	KIRC_SOMATICSNIPER	TCGA-A3-A6NN-01A-12D-A33K-10	TCGA-A3-A6NN-10A-01D-A33K-10
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.L1205V	0.4316	234.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.L1205V (Missense)	0	KIRC_SOMATICSNIPER	TCGA-B0-5707-01A-11D-1534-10	TCGA-B0-5707-11A-01D-1534-10
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.V504L	0.4313	211.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.V504L (Missense)	0	KIRC_SOMATICSNIPER	TCGA-EU-5907-01A-11D-1669-08	TCGA-EU-5907-10A-01D-1669-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.T2264I	0.2065	92.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.T2264I (Missense)	1	KIRC_SOMATICSNIPER	TCGA-B8-4622-01A-02D-1553-08	TCGA-B8-4622-11A-01D-1553-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.V1678G	0.2492	301.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.V1678G (Missense)	1	KIRC_SOMATICSNIPER	TCGA-CJ-4904-01A-02D-1429-08	TCGA-CJ-4904-11A-01D-1429-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L2965S	0.1942	103.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L2965S (Missense)	1	KIRC_SOMATICSNIPER	TCGA-CJ-4900-01A-01D-1462-08	TCGA-CJ-4900-11A-01D-1462-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.V1070E	0.2839	236.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.V1070E (Missense)	0	KIRC_SOMATICSNIPER	TCGA-CW-6087-01A-11D-1669-08	TCGA-CW-6087-11A-01D-1669-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Splice Site	p.X1183_splice	0.4921	63.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.X1183_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-B0-5098-01A-01D-1421-08	TCGA-B0-5098-11A-01D-1421-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.D324H	0.2525	99.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.D324H (Missense)	0	KIRC_SOMATICSNIPER	TCGA-B2-4101-01A-02D-1458-08	TCGA-B2-4101-11A-01D-1458-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.E17K	0.2206	68.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.E17K (Missense)	0	KIRC_SOMATICSNIPER	TCGA-BP-5009-01A-01D-1462-08	TCGA-BP-5009-11A-01D-1462-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.G2718R	0.5	20.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.G2718R (Missense)	1	KIRC_SOMATICSNIPER	TCGA-BP-5173-01A-01D-1429-08	TCGA-BP-5173-11A-01D-1429-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Splice Site	p.X813_splice	0.2952	166.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.X813_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-BP-4963-01A-01D-1462-08	TCGA-BP-4963-11A-01D-1462-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.Q1475H	0.1985	131.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.Q1475H (Missense)		KIRC_SOMATICSNIPER	TCGA-A3-3370-01A-02D-1421-08	TCGA-A3-3370-11A-01D-1421-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.I1487M	0.2616	172.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.I1487M (Missense)		KIRC_SOMATICSNIPER	TCGA-AS-3778-01A-01D-0966-08	TCGA-AS-3778-10A-01D-0966-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.S879Y	0.3784	37.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.S879Y (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-4913-01A-01D-1429-08	TCGA-CJ-4913-11A-01D-1429-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.L1137M	0.2056	107.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.L1137M (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-4918-01A-01D-1429-08	TCGA-CJ-4918-11A-01D-1429-08
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 4	version 2	0.286						Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	"In a cohort of 34 non-small cell lung cancer patients with pembrolizumab, the presence of a smoking signature (""transversion-high"" tumors) was associated with a higher overall response rate (56% in transversion-high tumors, vs. 17% in ""transversion-low"" [never-smoker] tumors), a higher rate of DCB (77% vs. 22%), and a longer PFS."	Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8.	https://doi.org/10.1126/science.aaa1348																	COSMIC Signature (version 2) 4 (29%)		KIRC_SOMATICSNIPER		
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X32_splice	0.8596	57.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X32_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-AK-3440-01A-01D-0966-08	TCGA-AK-3440-10A-01D-0966-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X261_splice	0.7121	132.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X261_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-BP-4770-01A-01D-1501-10	TCGA-BP-4770-11A-01D-1501-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193Y	0.5256	78.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193Y (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5117-01A-01D-1421-08	TCGA-B0-5117-11A-01D-1421-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V272M	0.4211	133.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V272M (Missense)		KIRC_SOMATICSNIPER	TCGA-CZ-5463-01A-01D-1501-10	TCGA-CZ-5463-11A-01D-1501-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.D281Y	0.1894	132.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D281Y (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-5677-01A-11D-1534-10	TCGA-CJ-5677-11A-01D-1534-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.2673	101.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-B0-5098-01A-01D-1421-08	TCGA-B0-5098-11A-01D-1421-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.S75R	0.3846	156.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.S75R (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5696-01A-11D-1534-10	TCGA-B0-5696-11A-01D-1534-10
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.A365V	0.2412	199.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.A365V (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-4920-01A-01D-1429-08	TCGA-CJ-4920-11A-01D-1429-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.S244L	0.2785	79.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.S244L (Missense)		KIRC_SOMATICSNIPER	TCGA-B8-5159-01A-01D-1421-08	TCGA-B8-5159-10A-01D-1421-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.R604*	0.6618	68.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R604* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-BP-4985-01A-01D-1462-08	TCGA-BP-4985-11A-01D-1462-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.A1382T	0.2105	95.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.A1382T (Missense)		KIRC_SOMATICSNIPER	TCGA-CZ-4856-01A-02D-1429-08	TCGA-CZ-4856-11A-01D-1429-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Nonsense	p.Y972*	0.3286	70.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.Y972* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-B8-5550-01A-01D-1534-10	TCGA-B8-5550-10A-01D-1535-10
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.E997*	0.2449	98.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.E997* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-BP-4983-01A-01D-1462-08	TCGA-BP-4983-11A-01D-1462-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.R720P	0.2048	166.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.R720P (Missense)		KIRC_SOMATICSNIPER	TCGA-B4-5836-01A-11D-1669-08	TCGA-B4-5836-10A-01D-1669-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.F290I	0.4135	104.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.F290I (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-5181-01A-01D-1429-08	TCGA-BP-5181-11A-01D-1429-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.L853M	0.25	76.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.L853M (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-4982-01A-01D-1462-08	TCGA-BP-4982-11A-01D-1462-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.M585L	0.2558	43.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.M585L (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5120-01A-01D-1421-08	TCGA-B0-5120-11A-01D-1421-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.K741E	0.3672	177.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.K741E (Missense)		KIRC_SOMATICSNIPER	TCGA-DV-A4W0-01A-11D-A25V-10	TCGA-DV-A4W0-10A-01D-A25V-10
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.S599I	0.3295	176.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.S599I (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-4976-01A-01D-1462-08	TCGA-BP-4976-11A-01D-1462-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.D53A	0.1821	335.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.D53A (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-4918-01A-01D-1429-08	TCGA-CJ-4918-11A-01D-1429-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D125G	0.1868	91.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D125G (Missense)	0	KIRC_SOMATICSNIPER	TCGA-B0-5077-01A-01D-1462-08	TCGA-B0-5077-11A-01D-1462-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E832K	0.227	141.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E832K (Missense)	0	KIRC_SOMATICSNIPER	TCGA-A3-3365-01A-01D-0966-08	TCGA-A3-3365-11A-01D-0966-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.F2841I	0.3981	108.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.F2841I (Missense)	0	KIRC_SOMATICSNIPER	TCGA-CZ-5982-01A-11D-1669-08	TCGA-CZ-5982-11A-01D-1669-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D189H	0.2024	578.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D189H (Missense)	0	KIRC_SOMATICSNIPER	TCGA-B2-5641-01A-01D-1534-10	TCGA-B2-5641-10A-01D-1535-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.A3297T	0.2908	196.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.A3297T (Missense)	0	KIRC_SOMATICSNIPER	TCGA-B8-4622-01A-02D-1553-08	TCGA-B8-4622-11A-01D-1553-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S313Y	0.1989	176.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S313Y (Missense)	0	KIRC_SOMATICSNIPER	TCGA-BP-4801-01A-02D-1421-08	TCGA-BP-4801-11A-01D-1421-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.I2177V	0.1942	103.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.I2177V (Missense)	0	KIRC_SOMATICSNIPER	TCGA-A3-3311-01A-01D-0966-08	TCGA-A3-3311-11A-01D-0966-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P1831L	0.15	100.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P1831L (Missense)	1	KIRC_SOMATICSNIPER	TCGA-BP-4998-01A-01D-1462-08	TCGA-BP-4998-11A-01D-1462-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2887T	0.3529	68.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2887T (Missense)	0	KIRC_SOMATICSNIPER	TCGA-A3-A8CQ-01A-11D-A36X-10	TCGA-A3-A8CQ-10A-01D-A370-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.N1309I	0.3569	339.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.N1309I (Missense)	1	KIRC_SOMATICSNIPER	TCGA-CZ-4853-01A-01D-1429-08	TCGA-CZ-4853-11A-01D-1429-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.N1309H	0.3493	335.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.N1309H (Missense)	1	KIRC_SOMATICSNIPER	TCGA-CZ-4853-01A-01D-1429-08	TCGA-CZ-4853-11A-01D-1429-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Nonsense	p.Y285*	0.3023	129.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.Y285* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-A3-3380-01A-01D-0966-08	TCGA-A3-3380-11A-01D-0966-08
Investigate Actionability	FDA-Approved		Clinical trial	Somatic Variant	PIK3CA	Nonsense	p.Y272*	0.3678	87.0	0.0	0.0		Investigate Actionability	Alpelisib	PI3K/AKT/mTOR inhibition	Targeted therapy	Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. 	Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Y272* (Nonsense)	1	KIRC_SOMATICSNIPER	TCGA-B8-5159-01A-01D-1421-08	TCGA-B8-5159-10A-01D-1421-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Nonsense	p.Y551*	0.2917	120.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.Y551* (Nonsense)	1	KIRC_SOMATICSNIPER	TCGA-MM-A563-01A-11D-A25V-10	TCGA-MM-A563-10A-01D-A25V-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.T238I	0.4351	308.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.T238I (Missense)	1	KIRC_SOMATICSNIPER	TCGA-B8-4621-01A-01D-1501-10	TCGA-B8-4621-10A-01D-1501-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.V109G	0.2663	338.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.V109G (Missense)	0	KIRC_SOMATICSNIPER	TCGA-CZ-5457-01A-01D-1501-10	TCGA-CZ-5457-11A-01D-1501-10
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.P15H	0.272	125.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.P15H (Missense)	0	KIRC_SOMATICSNIPER	TCGA-B0-5701-01A-11D-1534-10	TCGA-B0-5701-11A-01D-1534-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Nonsense	p.Q1088*	0.2115	104.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.Q1088* (Nonsense)	0	KIRC_SOMATICSNIPER	TCGA-B0-5706-01A-11D-1534-10	TCGA-B0-5706-11A-01D-1534-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.V868E	0.25	68.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.V868E (Missense)		KIRC_SOMATICSNIPER	TCGA-T7-A92I-01A-11D-A36X-10	TCGA-T7-A92I-10A-01D-A370-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Splice Site	p.X1204_splice	0.3036	56.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.X1204_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-T7-A92I-01A-11D-A36X-10	TCGA-T7-A92I-10A-01D-A370-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.D386N	0.3282	131.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.D386N (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-5181-01A-01D-1429-08	TCGA-BP-5181-11A-01D-1429-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.H206R	0.3762	101.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.H206R (Missense)		KIRC_SOMATICSNIPER	TCGA-B8-4622-01A-02D-1553-08	TCGA-B8-4622-11A-01D-1553-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.D1100N	0.2787	61.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.D1100N (Missense)	0	KIRC_SOMATICSNIPER	TCGA-B0-5693-01A-11D-1534-10	TCGA-B0-5693-11A-01D-1534-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Splice Site	p.X666_splice	0.2727	44.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.X666_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-G6-A8L7-01A-11D-A36X-10	TCGA-G6-A8L7-10A-01D-A370-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.V449E	0.4386	57.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.V449E (Missense)		KIRC_SOMATICSNIPER	TCGA-B8-4153-01B-11D-1669-08	TCGA-B8-4153-11A-01D-1669-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.L757V	0.301	103.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.L757V (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5115-01A-01D-1421-08	TCGA-B0-5115-11A-01D-1421-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Nonsense	p.E1031*	0.2395	167.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E1031* (Nonsense)	0	KIRC_SOMATICSNIPER	TCGA-B0-5121-01A-02D-1421-08	TCGA-B0-5121-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P1048R	0.3838	99.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P1048R (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-4995-01A-01D-1462-08	TCGA-BP-4995-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P42L	0.2632	76.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P42L (Missense)		KIRC_SOMATICSNIPER	TCGA-B4-5832-01A-11D-1669-08	TCGA-B4-5832-10A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.M586T	0.5534	103.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.M586T (Missense)		KIRC_SOMATICSNIPER	TCGA-A3-3367-01A-02D-1421-08	TCGA-A3-3367-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.I587T	0.5192	104.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.I587T (Missense)		KIRC_SOMATICSNIPER	TCGA-A3-A8OV-01A-11D-A36X-10	TCGA-A3-A8OV-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.E1287D	0.5691	615.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1287D (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-5682-01A-11D-1534-10	TCGA-CJ-5682-11A-01D-1535-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X239_splice	0.3187	91.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X239_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-CW-6093-01A-11D-1669-08	TCGA-CW-6093-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.K829T	0.2431	218.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.K829T (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5102-01A-01D-1421-08	TCGA-B0-5102-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.L423I	0.3008	133.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.L423I (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-4972-01A-01D-1462-08	TCGA-BP-4972-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.N574Y	0.52	50.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N574Y (Missense)		KIRC_SOMATICSNIPER	TCGA-GK-A6C7-01A-11D-A33K-10	TCGA-GK-A6C7-10B-01D-A33K-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.L614V	0.5377	106.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L614V (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5699-01A-11D-1534-10	TCGA-B0-5699-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X47_splice	0.5	138.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X47_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-CZ-5461-01A-01D-1501-10	TCGA-CZ-5461-11A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.Q200H	0.1818	77.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.Q200H (Missense)		KIRC_SOMATICSNIPER	TCGA-EU-5904-01A-11D-1669-08	TCGA-EU-5904-10A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X47_splice	0.5116	86.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X47_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-BP-5181-01A-01D-1429-08	TCGA-BP-5181-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.M586K	0.3597	139.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.M586K (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5096-01A-01D-1421-08	TCGA-B0-5096-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X176_splice	0.2873	355.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X176_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-BP-4801-01A-02D-1421-08	TCGA-BP-4801-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.C1233W	0.3796	108.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.C1233W (Missense)		KIRC_SOMATICSNIPER	TCGA-A3-3311-01A-01D-0966-08	TCGA-A3-3311-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.I709T	0.5263	152.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.I709T (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-4973-01A-01D-1462-08	TCGA-BP-4973-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X1537_splice	0.2632	95.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X1537_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-B0-5690-01A-11D-1534-10	TCGA-B0-5690-11A-01D-1534-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X238_splice	0.3092	152.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X238_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-A3-3323-01A-01D-0966-08	TCGA-A3-3323-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X177_splice	0.2677	198.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X177_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-B4-5377-01A-01D-1501-10	TCGA-B4-5377-10A-01D-1501-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.A1206E	0.3235	136.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.A1206E (Missense)		KIRC_SOMATICSNIPER	TCGA-A3-3322-01A-01D-0966-08	TCGA-A3-3322-11A-01D-0966-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.C707R	0.3987	158.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.C707R (Missense)		KIRC_SOMATICSNIPER	TCGA-A3-3385-01A-02D-1421-08	TCGA-A3-3385-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.N601K	0.2778	36.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N601K (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-4964-01A-01D-1462-08	TCGA-BP-4964-11A-01D-1462-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.T1202K	0.3535	99.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.T1202K (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-5186-01A-01D-1429-08	TCGA-BP-5186-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X332_splice	0.463	216.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X332_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-B0-5107-01A-01D-1421-08	TCGA-B0-5107-11A-01D-1421-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.Y580C	0.3495	103.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y580C (Missense)		KIRC_SOMATICSNIPER	TCGA-B8-4148-01A-02D-1386-10	TCGA-B8-4148-10A-01D-1251-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X1178_splice	0.3947	38.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X1178_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-CJ-6033-01A-11D-1669-08	TCGA-CJ-6033-11A-01D-1669-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.A581D	0.2371	97.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.A581D (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-4920-01A-01D-1429-08	TCGA-CJ-4920-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.Y718C	0.4375	304.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y718C (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-5200-01A-01D-1429-08	TCGA-BP-5200-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.L618H	0.5726	124.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L618H (Missense)		KIRC_SOMATICSNIPER	TCGA-CZ-4853-01A-01D-1429-08	TCGA-CZ-4853-11A-01D-1429-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.W1417G	0.2703	492.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.W1417G (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-5189-01A-02D-1429-08	TCGA-BP-5189-11A-01D-1429-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.D153Y	0.2097	186.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.D153Y (Missense)	1	KIRC_SOMATICSNIPER	TCGA-BP-5195-01A-02D-1429-08	TCGA-BP-5195-11A-01D-1429-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.N276K	0.4953	107.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.N276K (Missense)	1	KIRC_SOMATICSNIPER	TCGA-BP-5199-01A-01D-1429-08	TCGA-BP-5199-11A-01D-1429-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.S170N	0.322	264.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.S170N (Missense)	1	KIRC_SOMATICSNIPER	TCGA-A3-3316-01A-01D-0966-08	TCGA-A3-3316-11A-01D-0966-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Splice Site	p.X516_splice	0.3333	267.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.X516_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-B8-5550-01A-01D-1534-10	TCGA-B8-5550-10A-01D-1535-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1244H	0.3706	170.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1244H (Missense)		KIRC_SOMATICSNIPER	TCGA-A3-3320-01A-01D-0966-08	TCGA-A3-3320-11A-01D-0966-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.I2275T	0.2876	233.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.I2275T (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-4912-01A-01D-1429-08	TCGA-CJ-4912-11A-01D-1429-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S1961N	0.2537	67.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1961N (Missense)		KIRC_SOMATICSNIPER	TCGA-B8-5549-01A-01D-1534-10	TCGA-B8-5549-10A-01D-1535-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G665A	0.2468	77.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G665A (Missense)		KIRC_SOMATICSNIPER	TCGA-DV-A4W0-01A-11D-A25V-10	TCGA-DV-A4W0-10A-01D-A25V-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.T910M	0.2553	94.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.T910M (Missense)		KIRC_SOMATICSNIPER	TCGA-A3-A6NI-01A-11D-A33K-10	TCGA-A3-A6NI-10A-01D-A33K-10
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.E1047D	0.3758	149.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.E1047D (Missense)	0	KIRC_SOMATICSNIPER	TCGA-A3-A8OV-01A-11D-A36X-10	TCGA-A3-A8OV-10A-01D-A370-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1231T	0.2327	202.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1231T (Missense)		KIRC_SOMATICSNIPER	TCGA-A3-3319-01A-01D-0966-08	TCGA-A3-3319-11A-01D-0966-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1186G	0.3333	90.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1186G (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-4992-01A-01D-1462-08	TCGA-BP-4992-11A-01D-1462-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E365Q	0.3333	51.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E365Q (Missense)		KIRC_SOMATICSNIPER	TCGA-A3-3322-01A-01D-0966-08	TCGA-A3-3322-11A-01D-0966-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Nonsense	p.W265*	0.3	30.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.W265* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-BP-4986-01A-01D-1462-08	TCGA-BP-4986-11A-01D-1462-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.L30H	0.3023	129.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.L30H (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-5178-01A-01D-1429-08	TCGA-BP-5178-11A-01D-1429-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.D29H	0.3372	261.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.D29H (Missense)		KIRC_SOMATICSNIPER	TCGA-CZ-5456-01A-01D-1501-10	TCGA-CZ-5456-11A-01D-1501-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.G81D	0.1888	143.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.G81D (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5097-01A-01D-1421-08	TCGA-B0-5097-11A-01D-1421-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.L117F	0.2723	213.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.L117F (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5106-01A-01D-1421-08	TCGA-B0-5106-11A-01D-1421-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S91C	0.4009	212.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S91C (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5701-01A-11D-1534-10	TCGA-B0-5701-11A-01D-1534-10
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.I70L	0.2385	218.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.I70L (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-5004-01A-01D-1462-08	TCGA-BP-5004-11A-01D-1462-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.N1129Y	0.2108	185.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.N1129Y (Missense)		KIRC_SOMATICSNIPER	TCGA-B4-5836-01A-11D-1669-08	TCGA-B4-5836-10A-01D-1669-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.I201M	0.2176	680.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.I201M (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-4916-01A-01D-1429-08	TCGA-CJ-4916-11A-01D-1429-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Nonsense	p.Y318*	0.3014	292.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.Y318* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-MM-A563-01A-11D-A25V-10	TCGA-MM-A563-10A-01D-A25V-10
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.A458V	0.356	191.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.A458V (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5119-01A-02D-1421-08	TCGA-B0-5119-11A-01D-1421-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.A2000V	0.2975	363.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.A2000V (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5098-01A-01D-1421-08	TCGA-B0-5098-11A-01D-1421-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.I312L	0.1932	471.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.I312L (Missense)		KIRC_SOMATICSNIPER	TCGA-CZ-4859-01A-02D-1429-08	TCGA-CZ-4859-11A-01D-1429-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.R216Q	0.3361	238.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R216Q (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-5010-01A-02D-1421-08	TCGA-BP-5010-11A-01D-1421-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Nonsense	p.E1097*	0.2914	453.0	0.0	0.0																Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK2 p.E1097* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-CJ-5676-01A-11D-1534-10	TCGA-CJ-5676-11A-01D-1534-10
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.H1140Q	0.1988	161.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.H1140Q (Missense)		KIRC_SOMATICSNIPER	TCGA-B8-4622-01A-02D-1553-08	TCGA-B8-4622-11A-01D-1553-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.K535Q	0.28	100.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.K535Q (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5710-01A-11D-1669-08	TCGA-B0-5710-11A-01D-1669-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.N426D	0.451	204.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.N426D (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-4973-01A-01D-1462-08	TCGA-BP-4973-11A-01D-1462-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.T150I	0.2345	307.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.T150I (Missense)		KIRC_SOMATICSNIPER	TCGA-CW-5588-01A-01D-1534-10	TCGA-CW-5588-11A-01D-1535-10
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.E279K	0.3222	180.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.E279K (Missense)		KIRC_SOMATICSNIPER	TCGA-CZ-4853-01A-01D-1429-08	TCGA-CZ-4853-11A-01D-1429-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.Y1463S	0.1899	158.0	0.0	0.0																									MTOR p.Y1463S (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5697-01A-11D-1534-10	TCGA-B0-5697-11A-01D-1534-10
Biologically Relevant				Somatic Variant	CDKN2C	Missense	p.R39T	0.3004	263.0	0.0	0.0																									CDKN2C p.R39T (Missense)		KIRC_SOMATICSNIPER	TCGA-CZ-5451-01A-01D-1501-10	TCGA-CZ-5451-11A-01D-1501-10
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.H489Q	0.2778	90.0	0.0	0.0																									NTRK1 p.H489Q (Missense)		KIRC_SOMATICSNIPER	TCGA-DV-5576-01A-01D-1534-10	TCGA-DV-5576-10A-01D-1535-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T1977R	0.2462	199.0	0.0	0.0																									MTOR p.T1977R (Missense)		KIRC_SOMATICSNIPER	TCGA-B4-5832-01A-11D-1669-08	TCGA-B4-5832-10A-01D-1669-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1905D	0.3021	96.0	0.0	0.0																									ROS1 p.E1905D (Missense)		KIRC_SOMATICSNIPER	TCGA-A3-A6NI-01A-11D-A33K-10	TCGA-A3-A6NI-10A-01D-A33K-10
Biologically Relevant				Somatic Variant	ERG	Nonsense	p.Y201*	0.4568	162.0	0.0	0.0																									ERG p.Y201* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-B8-A54K-01A-11D-A33K-10	TCGA-B8-A54K-10A-01D-A33K-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T1977K	0.3495	309.0	0.0	0.0																									MTOR p.T1977K (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-4827-01A-02D-1421-08	TCGA-B0-4827-11A-01D-1421-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D780E	0.212	250.0	0.0	0.0																									ROS1 p.D780E (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-4869-01A-02D-1429-08	TCGA-CJ-4869-11A-01D-1429-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L1460P	0.3692	130.0	0.0	0.0																									MTOR p.L1460P (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5701-01A-11D-1534-10	TCGA-B0-5701-11A-01D-1534-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.C1483Y	0.2393	117.0	0.0	0.0																									MTOR p.C1483Y (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5696-01A-11D-1534-10	TCGA-B0-5696-11A-01D-1534-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.V1557I	0.1842	114.0	0.0	0.0																									ROS1 p.V1557I (Missense)		KIRC_SOMATICSNIPER	TCGA-B2-4102-01A-02D-1386-10	TCGA-B2-4102-11A-01D-1251-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L1460P	0.3088	204.0	0.0	0.0																									MTOR p.L1460P (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-5175-01A-01D-1429-08	TCGA-BP-5175-11A-01D-1429-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.A1459P	0.2202	218.0	0.0	0.0																									MTOR p.A1459P (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-5176-01A-01D-1429-08	TCGA-BP-5176-11A-01D-1429-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.K2595E	0.2603	411.0	0.0	0.0																									NF1 p.K2595E (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-5176-01A-01D-1429-08	TCGA-BP-5176-11A-01D-1429-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G422S	0.2821	39.0	0.0	0.0																									COL1A1 p.G422S (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5088-01A-01D-1462-08	TCGA-B0-5088-11A-01D-1462-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.V276M	0.3617	47.0	0.0	0.0																									SLC45A3 p.V276M (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-4976-01A-01D-1462-08	TCGA-BP-4976-11A-01D-1462-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.V2406M	0.3034	89.0	0.0	0.0																									MTOR p.V2406M (Missense)		KIRC_SOMATICSNIPER	TCGA-A3-A8OU-01A-11D-A36X-10	TCGA-A3-A8OU-10A-01D-A370-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.R735H	0.1772	79.0	0.0	0.0																									NTRK3 p.R735H (Missense)		KIRC_SOMATICSNIPER	TCGA-CZ-5461-01A-01D-1501-10	TCGA-CZ-5461-11A-01D-1501-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.S2215Y	0.6089	225.0	0.0	0.0																									MTOR p.S2215Y (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-5679-01A-11D-1534-10	TCGA-CJ-5679-11A-01D-1535-10
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.V684I	0.25	76.0	0.0	0.0																									NTRK2 p.V684I (Missense)		KIRC_SOMATICSNIPER	TCGA-G6-A5PC-01A-11D-A33K-10	TCGA-G6-A5PC-10A-01D-A33K-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.M409T	0.3636	22.0	0.0	0.0																									KEAP1 p.M409T (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-5183-01A-01D-1429-08	TCGA-BP-5183-11A-01D-1429-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D1512N	0.2991	331.0	0.0	0.0																									ROS1 p.D1512N (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5700-01A-11D-1534-10	TCGA-B0-5700-11A-01D-1534-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L1433S	0.2621	248.0	0.0	0.0																									MTOR p.L1433S (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-5001-01A-01D-1462-08	TCGA-BP-5001-11A-01D-1462-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.V654M	0.531	113.0	0.0	0.0																									RB1 p.V654M (Missense)		KIRC_SOMATICSNIPER	TCGA-BP-4770-01A-01D-1501-10	TCGA-BP-4770-11A-01D-1501-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E367V	0.3143	35.0	0.0	0.0																									MTOR p.E367V (Missense)		KIRC_SOMATICSNIPER	TCGA-MM-A564-01A-11D-A25V-10	TCGA-MM-A564-10A-01D-A25V-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.I2500M	0.2171	152.0	0.0	0.0																									MTOR p.I2500M (Missense)		KIRC_SOMATICSNIPER	TCGA-CW-5580-01A-01D-1669-08	TCGA-CW-5580-11A-02D-1669-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.G2745*	0.2554	231.0	0.0	0.0																									NF1 p.G2745* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-B0-5710-01A-11D-1669-08	TCGA-B0-5710-11A-01D-1669-08
Biologically Relevant				Somatic Variant	POT1	Splice Site	p.X182_splice	0.3147	143.0	0.0	0.0																									POT1 p.X182_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-CZ-5453-01A-01D-1501-10	TCGA-CZ-5453-11A-01D-1501-10
Biologically Relevant				Somatic Variant	BRD4	Missense	p.I233N	0.3636	77.0	0.0	0.0																									BRD4 p.I233N (Missense)		KIRC_SOMATICSNIPER	TCGA-CZ-5453-01A-01D-1501-10	TCGA-CZ-5453-11A-01D-1501-10
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.P424L	0.1645	152.0	0.0	0.0																									LIMK2 p.P424L (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-4945-01A-01D-1421-08	TCGA-B0-4945-11A-01D-1421-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.A263S	0.1899	158.0	0.0	0.0																									FGFR1 p.A263S (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-6031-01A-11D-1669-08	TCGA-CJ-6031-11A-01D-1669-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R755C	0.2821	78.0	0.0	0.0																									MTOR p.R755C (Missense)		KIRC_SOMATICSNIPER	TCGA-MM-A84U-01A-11D-A36X-10	TCGA-MM-A84U-10A-01D-A370-10
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Y2742*	0.3808	239.0	0.0	0.0																									NF1 p.Y2742* (Nonsense)		KIRC_SOMATICSNIPER	TCGA-A3-3382-01A-01D-0966-08	TCGA-A3-3382-11A-01D-0966-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.S262P	0.2171	129.0	0.0	0.0																									FIP1L1 p.S262P (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5812-01A-11D-1669-08	TCGA-B0-5812-11A-01D-1669-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2308Q	0.2886	149.0	0.0	0.0																									ROS1 p.E2308Q (Missense)		KIRC_SOMATICSNIPER	TCGA-B2-5633-01A-01D-A270-10	TCGA-B2-5633-10A-01D-A270-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L232V	0.2211	95.0	0.0	0.0																									ROS1 p.L232V (Missense)		KIRC_SOMATICSNIPER	TCGA-B8-A54J-01A-11D-A33K-10	TCGA-B8-A54J-10A-01D-A33K-10
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.W10C	0.2959	98.0	0.0	0.0																									FGFR1 p.W10C (Missense)		KIRC_SOMATICSNIPER	TCGA-A3-3385-01A-02D-1421-08	TCGA-A3-3385-11A-01D-1421-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.V629L	0.3012	83.0	0.0	0.0																									FGFR1 p.V629L (Missense)		KIRC_SOMATICSNIPER	TCGA-CW-6090-01A-11D-1669-08	TCGA-CW-6090-11A-01D-1669-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.F1888L	0.5	134.0	0.0	0.0																									MTOR p.F1888L (Missense)		KIRC_SOMATICSNIPER	TCGA-CZ-4866-01A-01D-1501-10	TCGA-CZ-4866-11A-01D-1501-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.V2422I	0.3918	97.0	0.0	0.0																									MTOR p.V2422I (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5712-01A-11D-1669-08	TCGA-B0-5712-11A-01D-1669-08
Biologically Relevant				Somatic Variant	ROS1	Splice Site	p.X1441_splice	0.2701	274.0	0.0	0.0																									ROS1 p.X1441_splice (Splice Site)		KIRC_SOMATICSNIPER	TCGA-A3-3387-01A-01D-1534-10	TCGA-A3-3387-11A-01D-1534-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T1977R	0.2391	230.0	0.0	0.0																									MTOR p.T1977R (Missense)		KIRC_SOMATICSNIPER	TCGA-B4-5844-01A-11D-1669-08	TCGA-B4-5844-10A-01D-1669-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D609N	0.1967	61.0	0.0	0.0																									NTRK3 p.D609N (Missense)		KIRC_SOMATICSNIPER	TCGA-B8-4148-01A-02D-1386-10	TCGA-B8-4148-10A-01D-1251-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.I2228T	0.4634	41.0	0.0	0.0																									MTOR p.I2228T (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5098-01A-01D-1421-08	TCGA-B0-5098-11A-01D-1421-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.I500L	0.422	282.0	0.0	0.0																									MLH1 p.I500L (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5098-01A-01D-1421-08	TCGA-B0-5098-11A-01D-1421-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S856N	0.2963	108.0	0.0	0.0																									NF1 p.S856N (Missense)		KIRC_SOMATICSNIPER	TCGA-B0-5098-01A-01D-1421-08	TCGA-B0-5098-11A-01D-1421-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.A1519T	0.2131	61.0	0.0	0.0																									MTOR p.A1519T (Missense)		KIRC_SOMATICSNIPER	TCGA-CJ-6027-01A-11D-1669-08	TCGA-CJ-6027-11A-01D-1669-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.Y800C	0.3725	102.0	0.0	0.0																									ROS1 p.Y800C (Missense)		KIRC_SOMATICSNIPER	TCGA-G6-A8L7-01A-11D-A36X-10	TCGA-G6-A8L7-10A-01D-A370-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.L2209S	0.3303	221.0	0.0	0.0																									NF1 p.L2209S (Missense)		KIRC_SOMATICSNIPER	TCGA-CZ-4853-01A-01D-1429-08	TCGA-CZ-4853-11A-01D-1429-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.K1452N	0.305	141.0	0.0	0.0																									MTOR p.K1452N (Missense)		KIRC_SOMATICSNIPER	TCGA-CZ-5987-01A-11D-1669-08	TCGA-CZ-5987-11A-01D-1669-08
Biologically Relevant				Mutational Signature	COSMIC Signature 19	version 2	0.316																													COSMIC Signature (version 2) 19 (32%)		KIRC_SOMATICSNIPER		
